A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies.

[1]  A. Dueñas-González,et al.  Response to gefitinib in bronchioloalveolar carcinoma in the absence of EGFR mutation. , 2005, Lung cancer.

[2]  A. Oza,et al.  Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Renato Martins,et al.  Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.

[4]  S. Toyooka,et al.  EGFR mutation and response of lung cancer to gefitinib. , 2005, The New England journal of medicine.

[5]  D. Xing,et al.  Modeling Resistance to Pathway-Targeted Therapy in Ovarian Cancer , 2005, Cell cycle.

[6]  L. Schwartz,et al.  Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Y. Kim,et al.  Predictors of the Response to Gefitinib in Refractory Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[8]  H. Lenz,et al.  Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study. , 2005, Gynecologic oncology.

[9]  M. Seiden,et al.  Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies , 2005, Current treatment options in oncology.

[10]  A. Berkenblit,et al.  A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. , 2004, Gynecologic oncology.

[11]  D. Alberts,et al.  Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study. , 2004, Gynecologic oncology.

[12]  A. Jakobsen,et al.  Prognostic significance of p53, Her‐2, and EGFR overexpression in borderline and epithelial ovarian cancer , 2004, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[13]  Steven Sun,et al.  Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. , 2004, Gynecologic oncology.

[14]  Armando Santoro,et al.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.

[15]  C. Elie,et al.  Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group) , 2004, British Journal of Cancer.

[16]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[17]  Neal J Meropol,et al.  Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging , 2004, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[19]  F. Akiyama,et al.  Efficacy and Safety of Trastuzumab as a Single Agent in Heavily Pretreated Patients with Her-2/NEU-Overexpressing Metastatic Breast Cancer , 2004, Tumori.

[20]  I. Bauerfeind,et al.  EGFR, HER-2/neu, Cyclin D1, p21 and p53 in Correlation to Cell Proliferation and Steroid Hormone Receptor Status in Ductal Carcinoma in situ of the Breast , 2003, Breast Cancer Research and Treatment.

[21]  S. Cannistra.  Cancer of the ovary. , 1993, The New England journal of medicine.

[22]  Cetuximab: in the treatment of metastatic colorectal cancer. , 2004, Drugs.

[23]  J. Baselga,et al.  Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  U. Matulonis,et al.  Phase II trial of anastrozole in women with asymptomatic müllerian cancer. , 2003, Gynecologic oncology.

[25]  A. Ullrich,et al.  EGFR signal transactivation in cancer cells. , 2003, Biochemical Society transactions.

[26]  F. Amant,et al.  Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer. , 2003, Gynecologic oncology.

[27]  I. Vergote,et al.  Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study. , 2003, Gynecologic oncology.

[28]  K. Darcy,et al.  Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. Gore,et al.  Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. , 2002, The Lancet. Oncology.

[30]  M. Mottolese,et al.  Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer. , 2002, Gynecologic oncology.

[31]  D Guthrie,et al.  Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[33]  T. Seidal,et al.  The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma , 2000, International Journal of Gynecologic Cancer.

[34]  M. Campiglio,et al.  Characteristics of EGFR family‐mediated HRG signals in human ovarian cancer , 1999, Journal of cellular biochemistry.

[35]  A Gordon,et al.  Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  H. Heinzl,et al.  EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. , 1997, Anticancer research.